Sigachi Industries begins disbursing Interim ex-gratia to families of deceased

Laurus Labs to invest €5 million in JV KRKA Pharma

The purpose of this investment is to meet the expenditure relating to the civil works to be undertaken for setting up of a manufacturing facility

RPG Life Sciences appoints Deepak Shukla as Chief Executive - API Business

Deepak has around 25 years of work experience with reputed companies viz. UPL Group, Teva Group, AkzoNobel India, Ranbaxy Laboratories, and Dr. Reddy’s Laboratories

Jagsonpal Pharmaceuticals Q1 FY26 revenue up 23.1%

Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution

Laurus Labs consolidated Q1 FY2026 PAT at Rs. 163.02 Cr

Laurus Labs has reported total income of Rs. 1,580 crores during the period ended June 30, 2025

Solara Active Pharma Sciences consolidated Q1FY26 PAT rises to Rs. 10.52 Cr

Solara Active Pharma Sciences has reported total income of Rs. 320.13 crores during the period ended June 30, 2025

Cipla reports Q1 FY2025-26 consolidated profit up at Rs. 1,297.62 Cr

Cipla has reported total income of Rs. 7,216.03 crores during the period ended June 30, 2025

RPG Life Sciences Q1 FY2026 PAT slips to Rs. 26.29 Cr

RPG Life Sciences has reported total income of Rs. 174.15 crores during the period ended June 30, 2025

NATCO Pharma API unit in Mekaguda receives EIR from USFDA

The company received one observation in the Form-483

Lupin receives USFDA approvals for Liraglutide and Glucagon injectable products

Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India